Bioactieve stoffen lijken veelbelovend tegen hepatitis C*
Uit een laboratoriumstudie lijkt het dat de bioactieve stoffen
catechinen en naringeninen de virusinfectie
hepatitis C goed kunnen bestrijden. In een eerdere studie hadden de wetenschappers al gevonden dat de bioactieve stof
quercetine de virusinfectie tot staan kon brengen. Wetenschappers zijn op zoek naar andere behandelingen van hepatitis C omdat de huidige aanpak met medicijnen slechts in 50% succes heeft en met veel ernstige bijwerkingen te paard kan gaan, waardoor mensen de behandeling staken. De bioactieve stoffen zoals quercetine, catechinen en naringeninen vertonen geen enkele bijwerking. De wetenschappers gaan nu een studie bij mensen opzetten.
New Compounds Show Promise Against Hepatitis C Infection
Approximately 270-300 million people worldwide are infected with hepatitis C, and about 1%-2% of the U.S. population is infected. This infectious disease can lead to scarring of the liver, cirrhosis, and eventually liver failure. A significant number of infected patients develop liver disease or cancer. The current standard treatment is interferon, which has only a 50% success rate. Compounding the 50% failure rate are severe side effects which lead many people to discontinue treatment.
Dr. Samuel Wheeler French Jr., MD, PhD, Assistant Professor of Pathology and Laboratory Medicine at UCLA and researcher at UCLA's Jonsson Comprehensive Cancer Center, is a liver pathologist who is currently developing a proteomic-based program to study the development of liver cancer from hepatitis C viral infection. His most recent study results, to be presented in an American Society for Investigative Pathology (ASIP) symposium on "Pathobiology of Liver Injury and Fibrosis" at Experimental Biology 2011, evaluate the effects of several flavonoids on hepatitis C viral infection.
Previously, Dr. French has shown that quercetin, a plant-derived bioflavonoid used by some as a nutritional supplement, attenuates Hepatitis C virus production with no cell toxicity. In his most recent research, French and colleagues found that two other bioflavonoids, catechin and naringenin, displayed antiviral activity on tissue culture. The next step is to determine through a Phase I Clinical Trial that they are safe for patients with chronic hepatitis C infection.
"We now have several new compounds we can test to see if they reduce virus infection," said Dr. French. "The positive thing about this family of compounds is that they are nontoxic, and can be taken at high doses. Bioflavonoids represent a very promising therapy with very few side effects that could help millions of
people."
(Augustus 2011)
Reacties:
